Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: Benzinga
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.945
Low
5.00
Averages
7.33
High
9.00
Current: 5.945
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Collaborates with SFDA to Advance BCG and ANKTIVA
- Regulatory Submission Encouragement: The SFDA has encouraged ImmunityBio to submit a regulatory package for recombinant BCG to address the ongoing BCG shortage in Saudi Arabia, with submission expected in the coming weeks, thereby enhancing treatment accessibility for bladder cancer patients in the region.
- ANKTIVA Expansion Discussions: ImmunityBio has initiated discussions with the SFDA regarding the expansion of ANKTIVA in combination with checkpoint inhibitors to additional tumor types, building on the accelerated approval granted in January 2026 for metastatic non-small cell lung cancer, which enhances the company's competitive position in the market.
- Clinical Trial Results: The QUILT-3.055 trial demonstrated that ANKTIVA rescues checkpoint inhibitor activity across multiple tumor types, with a median overall survival of 14.1 months in NSCLC patients, indicating its potential in tumor immunotherapy and possibly paving the way for future regulatory approvals.
- Regional Strategic Development: ImmunityBio plans to establish a regional office in Saudi Arabia to support physicians and patients across the Middle East and North Africa, reflecting the company's commitment to the market and accelerating the development and commercialization of innovative therapies through collaboration with the Saudi-USA Biotech Alliance.
See More
ImmunityBio Engages SFDA to Expand ANKTIVA Use Across Tumor Types
- ANKTIVA Expansion Discussions: ImmunityBio has initiated discussions with the Saudi Food and Drug Authority (SFDA) to explore the use of ANKTIVA in combination with checkpoint inhibitors for multiple tumor types, aiming to enhance the company's competitive position in the oncology immunotherapy market.
- Positive Market Reaction: Following the discussions with the SFDA, ImmunityBio's shares rose approximately 6% in premarket trading, reflecting investor optimism regarding the company's future regulatory submissions and market expansion, with plans to file within the next few weeks.
- Clinical Data Support: ANKTIVA received accelerated approval in Saudi Arabia in January 2026, with data from the QUILT-3.055 Phase 2b trial showing its ability to restore checkpoint inhibitor activity across various cancers, particularly in relapsed lung cancer patients, where the median overall survival reached 14.1 months, indicating significant therapeutic potential.
- Regional Strategic Positioning: ImmunityBio has established a wholly owned subsidiary in Saudi Arabia to support regulatory filings and clinical development, demonstrating the company's commitment to the Middle East and North Africa markets, aiming to enhance market penetration and meet the growing demand for treatments.
See More
S&P 500 Futures Decline in Pre-Market Session; Masimo and Enlight Renewable Energy Take the Lead
- Masimo Corp. Performance: Masimo Corp. (MASI) saw a significant increase of 34.5% in pre-market trading.
- Enlight Renewable Energy Ltd. Performance: Enlight Renewable Energy Ltd. (ENLT) experienced an 8.0% rise in pre-market trading.
- Market Context: The U.S. stock markets are set to open in two hours, indicating potential volatility.
- Investor Sentiment: The pre-market gains for both companies suggest positive investor sentiment ahead of the market opening.
See More
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
- Significant Price Surge: ZIM Integrated Shipping shares jumped 38.1% to $30.65 in pre-market trading, indicating strong market optimism regarding its future performance, which may attract more investor interest.
- Positive Market Reaction: This notable price fluctuation reflects investor confidence in the company's potential growth and profitability, potentially leading to further increases in subsequent trading days and enhancing its market position.
- Industry-Wide Impact: The surge in ZIM's stock price could influence investor sentiment across the shipping industry, prompting fluctuations in the stock prices of other related companies and affecting overall industry performance.
- Increased Investor Attention: As the stock price rises, ZIM may attract more attention from analysts and investors, further driving its market performance and trading volume, thereby strengthening the company's competitiveness in the shipping market.
See More
Hapag-Lloyd Acquires ZIM for $4.2 Billion Amid Market Volatility
- Acquisition Deal: Hapag-Lloyd has signed a definitive agreement to acquire ZIM Integrated Shipping for $4.2 billion, representing a 58% premium over ZIM's recent closing price, which will enhance Hapag-Lloyd's competitive position in the global shipping market.
- Market Sentiment: Despite the acquisition news, U.S. stock futures fell sharply after the Presidents' Day break, with Nasdaq futures down 0.6%, indicating ongoing investor concerns regarding the 'AI disruption' trade.
- Economic Data Focus: Investors are closely monitoring the upcoming ADP Weekly Employment Change and Empire State Manufacturing Index releases, as these data points could influence market sentiment and guide future investment decisions.
- Earnings Watch: The market will be looking for quarterly reports from companies like Medtronic and LabCorp, as their performance will provide further insights into economic health and could impact the performance of related stocks.
See More
ImmunityBio Criticizes FDA for Unequal Approval Standards
- FDA Approval Controversy: ImmunityBio's Executive Chairman Patrick Soon-Shiong criticized the FDA for imposing stricter approval standards on Anktiva, requiring randomized trials while allowing Keytruda to expand indications through single-arm trials, which limits Anktiva's approval to bladder cancer and affects patient treatment options.
- Urgent Patient Demand: Soon-Shiong highlighted that over 13,000 Americans are seeking access to Anktiva, but due to FDA restrictions, they can only receive the drug for specific types of bladder cancer, showcasing the regulatory bottleneck and its unreasonable nature.
- International Market Dynamics: Despite facing approval hurdles in the U.S., Anktiva has received a conditional marketing authorization recommendation from the European Medicines Agency and has been approved in Saudi Arabia, indicating potential for broader application in international markets.
- Clinical Research Progress: ImmunityBio recently launched a mid-stage study evaluating the efficacy of Anktiva combined with Rituximab in patients without the need for chemotherapy, aiming to further validate its potential in treating indolent B-cell non-Hodgkin lymphoma, which may pave the way for future FDA applications.
See More
ImmunityBio Collaborates with SFDA to Advance BCG and ANKTIVA
- Regulatory Submission Encouragement: The SFDA has encouraged ImmunityBio to submit a regulatory package for recombinant BCG to address the ongoing BCG shortage in Saudi Arabia, with submission expected in the coming weeks, thereby enhancing treatment accessibility for bladder cancer patients in the region.
- ANKTIVA Expansion Discussions: ImmunityBio has initiated discussions with the SFDA regarding the expansion of ANKTIVA in combination with checkpoint inhibitors to additional tumor types, building on the accelerated approval granted in January 2026 for metastatic non-small cell lung cancer, which enhances the company's competitive position in the market.
- Clinical Trial Results: The QUILT-3.055 trial demonstrated that ANKTIVA rescues checkpoint inhibitor activity across multiple tumor types, with a median overall survival of 14.1 months in NSCLC patients, indicating its potential in tumor immunotherapy and possibly paving the way for future regulatory approvals.
- Regional Strategic Development: ImmunityBio plans to establish a regional office in Saudi Arabia to support physicians and patients across the Middle East and North Africa, reflecting the company's commitment to the market and accelerating the development and commercialization of innovative therapies through collaboration with the Saudi-USA Biotech Alliance.
See More
ImmunityBio Engages SFDA to Expand ANKTIVA Use Across Tumor Types
- ANKTIVA Expansion Discussions: ImmunityBio has initiated discussions with the Saudi Food and Drug Authority (SFDA) to explore the use of ANKTIVA in combination with checkpoint inhibitors for multiple tumor types, aiming to enhance the company's competitive position in the oncology immunotherapy market.
- Positive Market Reaction: Following the discussions with the SFDA, ImmunityBio's shares rose approximately 6% in premarket trading, reflecting investor optimism regarding the company's future regulatory submissions and market expansion, with plans to file within the next few weeks.
- Clinical Data Support: ANKTIVA received accelerated approval in Saudi Arabia in January 2026, with data from the QUILT-3.055 Phase 2b trial showing its ability to restore checkpoint inhibitor activity across various cancers, particularly in relapsed lung cancer patients, where the median overall survival reached 14.1 months, indicating significant therapeutic potential.
- Regional Strategic Positioning: ImmunityBio has established a wholly owned subsidiary in Saudi Arabia to support regulatory filings and clinical development, demonstrating the company's commitment to the Middle East and North Africa markets, aiming to enhance market penetration and meet the growing demand for treatments.
See More
S&P 500 Futures Decline in Pre-Market Session; Masimo and Enlight Renewable Energy Take the Lead
- Masimo Corp. Performance: Masimo Corp. (MASI) saw a significant increase of 34.5% in pre-market trading.
- Enlight Renewable Energy Ltd. Performance: Enlight Renewable Energy Ltd. (ENLT) experienced an 8.0% rise in pre-market trading.
- Market Context: The U.S. stock markets are set to open in two hours, indicating potential volatility.
- Investor Sentiment: The pre-market gains for both companies suggest positive investor sentiment ahead of the market opening.
See More
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
- Significant Price Surge: ZIM Integrated Shipping shares jumped 38.1% to $30.65 in pre-market trading, indicating strong market optimism regarding its future performance, which may attract more investor interest.
- Positive Market Reaction: This notable price fluctuation reflects investor confidence in the company's potential growth and profitability, potentially leading to further increases in subsequent trading days and enhancing its market position.
- Industry-Wide Impact: The surge in ZIM's stock price could influence investor sentiment across the shipping industry, prompting fluctuations in the stock prices of other related companies and affecting overall industry performance.
- Increased Investor Attention: As the stock price rises, ZIM may attract more attention from analysts and investors, further driving its market performance and trading volume, thereby strengthening the company's competitiveness in the shipping market.
See More
Hapag-Lloyd Acquires ZIM for $4.2 Billion Amid Market Volatility
- Acquisition Deal: Hapag-Lloyd has signed a definitive agreement to acquire ZIM Integrated Shipping for $4.2 billion, representing a 58% premium over ZIM's recent closing price, which will enhance Hapag-Lloyd's competitive position in the global shipping market.
- Market Sentiment: Despite the acquisition news, U.S. stock futures fell sharply after the Presidents' Day break, with Nasdaq futures down 0.6%, indicating ongoing investor concerns regarding the 'AI disruption' trade.
- Economic Data Focus: Investors are closely monitoring the upcoming ADP Weekly Employment Change and Empire State Manufacturing Index releases, as these data points could influence market sentiment and guide future investment decisions.
- Earnings Watch: The market will be looking for quarterly reports from companies like Medtronic and LabCorp, as their performance will provide further insights into economic health and could impact the performance of related stocks.
See More
ImmunityBio Criticizes FDA for Unequal Approval Standards
- FDA Approval Controversy: ImmunityBio's Executive Chairman Patrick Soon-Shiong criticized the FDA for imposing stricter approval standards on Anktiva, requiring randomized trials while allowing Keytruda to expand indications through single-arm trials, which limits Anktiva's approval to bladder cancer and affects patient treatment options.
- Urgent Patient Demand: Soon-Shiong highlighted that over 13,000 Americans are seeking access to Anktiva, but due to FDA restrictions, they can only receive the drug for specific types of bladder cancer, showcasing the regulatory bottleneck and its unreasonable nature.
- International Market Dynamics: Despite facing approval hurdles in the U.S., Anktiva has received a conditional marketing authorization recommendation from the European Medicines Agency and has been approved in Saudi Arabia, indicating potential for broader application in international markets.
- Clinical Research Progress: ImmunityBio recently launched a mid-stage study evaluating the efficacy of Anktiva combined with Rituximab in patients without the need for chemotherapy, aiming to further validate its potential in treating indolent B-cell non-Hodgkin lymphoma, which may pave the way for future FDA applications.
See More
